ArticleCureus2025
Spontaneous Regression of a Retinal Astrocytic Hamartoma in an Adolescent With Tuberous Sclerosis Complex.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Tuberous sclerosis complex (TSC) is a rare, autosomal dominant syndrome arising from mutations in tumor suppressor genes. Common ophthalmic findings include retinal astrocytic hamartomas (RAHs), retinal achromic patches, and eyelid angiofibromas. In this article, we report a case of an adolescent girl with TSC found to have bilateral RAHs, highlighting the necessity for routine fundus examinations in patients with TSC. Additionally, our case is a rare example of a RAH that spontaneously regressed. RAHs can develop at any age and may rarely threaten vision with potential complications including vitreous hemorrhage, vitreous seeding, exudative retinal detachment, glaucoma, optic nerve invasion, globe perforation, and blindness. If detected early, vision-threatening RAHs may benefit from a variety of therapies, including argon laser photocoagulation, photodynamic therapy, subthreshold micropulse laser photocoagulation, and intravitreal anti-vascular endothelial growth factor (VEGF) agents. A medical history and knowledge of typical manifestations of this phakomatosis and their corresponding physical examination and ophthalmic imaging characteristics aid in the diagnosis. Most retinal astrocytic hamartomas do not cause vision deficit and may be safely observed, and a subset, as seen in this case, may spontaneously regress.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.